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A B S T R A C T   
Alzheimer’s disease (AD) is a complex disease that is mediated by numerous factors and manifests in various 
forms. A systems biology approach to studying AD involves analyses of various body systems, biological scales, 
environmental elements, and clinical outcomes to understand the genotype to phenotype relationship that 
potentially drives AD development. Currently, there are many research investigations probing how modifiable 
and nonmodifiable factors impact AD symptom presentation. This review specifically focuses on how imaging 
modalities can be integrated into systems biology approaches using model mouse populations to link brain level 
functional and structural changes to disease onset and progression. Combining imaging and omics data promotes 
the classification of AD into subtypes and paves the way for precision medicine solutions to prevent and treat AD.   
1. Introduction 
Alzheimer’s Disease (AD) is a multifaceted neurodegenerative dis-
ease that currently has no cure or clinically effective treatments. AD is 
the most common form of dementia, the 7th leading cause of death 
globally, and the 6th leading cause in the USA, with more than 6.2 
million Americans living with this disease (The Top 10 Causes of Death, 
2020). This frequency is estimated to further increase in the US by 2050; 
however, these estimations may not accurately reflect disease preva-
lence as many cases likely go undetected due to diagnostic challenges 
that arise from the highly variable presentation of the disease (Taylor 
et al., 2017). The lack of consensus about disease manifestation and its 
typical progression emphasizes the need for improved predictive diag-
nostic factors. Additionally, the field would benefit from collectively 
taking a more holistic approach to studying this disease as a series of 
interacting biological systems and factors rather than examining each 
involved system in isolation. 
The aim of this review is to describe studies that have aided in the 
understanding and classification of AD using systems biology ap-
proaches that exploit imaging methods. We summarize the various 
factors that influence AD progression, the variable presentation of AD 
among individuals, and how the field of AD research is evolving to take 
more systems-level approaches. We focus on studies that successfully 
link the components of systems biology to clinical outcomes, specifically 
using imaging data as an intermediate to analyze disease state. 
1.1. Types of AD 
AD is a debilitating disease that causes progressive decline in 
cognitive and motor function that significantly reduces one’s quality of 
life. A definitive diagnosis can only be determined by the postmortem 
detection of amyloid-beta (Aβ) plaques and tau neurofibrillary tangles 
(NFT). While these two hallmarks of AD correlate with disease pro-
gression, their presence is not completely predictive of AD development 
as their prevalence varies based on type of AD. Plaque and tangle pa-
thology only account for about 41% of variation in cognitive decline 
between individuals with AD (2020 Alzheimer’s Disease Facts and Fig-
ures, 2020; Boyle et al., 2013). 
Traditionally, AD cases are initially classified by genetic inheritance 
pattern and the age at onset (AAO) of disease symptoms. Thereafter, AD 
progression is characterized on a continuum based on the extent of 
cognitive decline and pathological load(s) (Braak et al., 2006; Braak and 
Braak, 1991; Markesbery, 1997). The two broad categories of AD are 
early onset AD (EOAD) and sporadic late onset AD (LOAD). EOAD can be 
subdivided to reflect cases that result from mendelian or nonmendelian 
inheritance of casual mutations. Mendelian, or familial, AD (FAD), is 
characterized by the inheritance of highly penetrant, autosomal domi-
nant causal mutations in the genes APP, PSEN1, and PSEN2 (Mendez, 
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2017; Tanzi, 2012). These mutations only account for a small percentage 
of FAD cases, and variation in age of onset and severity of symptoms 
exists among individuals, suggesting that additional genetic and envi-
ronmental factors modify disease pathogenesis and clinical manifesta-
tion (Ryman et al., 2014). Nonmendelian, or non-familial, EOAD is 
classified by the aggressive onset of cognitive symptoms before the age 
of 65; however, individuals with this form of AD develop symptoms 
sporadically and have inconsistent inheritance patterns (Joshi et al., 
2012; Reitz et al., 2020). 
LOAD is the most common form of AD, occurring in individuals 65 
years and older, with highly variable presentation of symptoms, which 
also vary in severity. Age is the greatest risk factor for LOAD, but 
research suggests that there are also additional causal genetic and 
environmental factors. According to twin and family studies, LOAD is 
approximately 58% to 79% heritable and gene variants in APOE and 
TREM2 are established LOAD risk factors (Belloy et al., 2019; Corder 
et al., 1993; Gatz et al., 2006; Pedersen et al., 2004; Räihä et al., 1996; 
Roses, 1996; Strittmatter et al., 1993a; Strittmatter et al., 1993b). To 
date, more than 30 genetic risk variants and susceptibility loci have been 
identified by genome-wide association studies (GWAS) or phenome- 
wide association studies (PheWAS), including CLU, BIN1, ABCA7, and 
SORL1 (Andrews et al., 2020; Backman et al., 2021; Bellenguez et al., 
2020; Kunkle et al., 2019; Lambert et al., 2013; Pimenova et al., 2018; 
Wang et al., 2016b; Wightman et al., 2021; Zhao et al., 2019). Indi-
vidually, each AD-associated locus or gene variant has a relatively small 
effect on the likelihood of developing AD. AD risk increases with each 
genetic variant inherited, which overall has an additive effect on AD 
severity; this is referred to as polygenic risk. The compilation of genes 
identified using GWAS allows for the assignment of polygenetic risk 
scores which can aid in predicting risk or disease progression; however, 
additional factors such as sex and environment also need to be taken into 
consideration to gain a comprehensive understanding of the disease and 
how it manifests in individuals (Dunn et al., 2019). 
Recent studies have begun to reprioritize GWAS hits by integrating 
multiscale data collected from relevant brain regions of interest (e.g. 
hippocampus) to generate network-based functional prediction methods 
and gene-related imaging biomarkers (e.g. brain atrophy) (Elliott et al., 
2018; Knutson et al., 2020; Meng et al., 2020; Shen et al., 2010; 
Wachinger et al., 2018; Xu et al., 2017). Additionally, GWAS methods 
and imaging data have been aggregated to identify loci associated with 
image-derived phenotypes (Cruchaga et al., 2013; Elsheikh et al., 2020; 
Furney et al., 2011; Grasby et al., 2020; Hofer et al., 2020; Li et al., 2017; 
Matoba and Stein, 2021; Meda et al., 2012; Nativio et al., 2020; Ram-
anan et al., 2015; Smith et al., 2021). Ultimately, this method of 
combining omics and imaging data to link changes in gene expression, 
the biological pathways associated with those genes, and functional and 
structural changes in the brain, may allow researchers to further assess 
both EOAD and LOAD and potentially narrow down these disease clas-
sifications in subtypes. 
1.2. Sex differences 
Females have a higher prevalence of AD and experience more severe 
cognitive and noncognitive symptoms than men (2019 Alzheimer’s 
Disease Facts and Figures, 2019). Previously, this unequal distribution 
of cases was attributed to the longer average lifespan of females, but in 
recent years more specific evidence linking sex and AD progression has 
been identified (Mielke et al., 2014). Among those with FAD, global 
amyloid load and greater tau deposition in the frontal, inferior parietal, 
and temporal lobes was higher in females (Groh et al., 2020; Oveis-
gharan et al., 2018). Interestingly, sex differences in AD development 
varies based on pathology load. Both males and females with low pa-
thology load have similar risks of developing AD, whereas in individuals 
with moderate to high levels of pathology, disease risk is greater in fe-
males (Barnes et al., 2005). Females diagnosed with AD also experience 
a faster progression of hippocampal atrophy compared to males 
(Ardekani et al., 2016). With increased numbers of study participants to 
enhance statistical power, as well as computational resources and large 
collaborative research teams, sex-stratified GWAS have led to identifi-
cation of sex-specific genetic factors that drive pathology and AD pro-
gression (Deming et al., 2018; Nazarian et al., 2019; Prokopenko et al., 
2020). Expression quantitative trait loci (eQTL) mapping was performed 
on putative sex-specific GWAS loci to identify candidate genes that were 
associated with a range of AD markers for each sex. Using this method, a 
single nucleotide polymorphism (SNP) of the candidate locus MAPT was 
positively associated with NFT specifically in males (Dumitrescu et al., 
2019). Until recently, sex was typically controlled or adjusted for as a 
demographic factor in most human studies, but as experiments continue 
to highlight the importance of sex-specific differences in AD risk and 
development, it is apparent that sex needs to be more thoroughly studied 
in a controlled manner, while taking environmental exposures into 
consideration, via longitudinal investigations. 
1.3. Environmental control 
The relationship between AD and environmental factors has 
increasingly become a research topic of interest as correlations and 
comorbidities between AD and modifiable behaviors have been uncov-
ered. Strikingly, recent meta-analyses have found that up to 40% of 
dementia and AD cases may be attributed to controllable environmental 
factors throughout a person’s life (Barnes and Yaffe, 2011; Livingston 
et al., 2020; Livingston et al., 2017). Links between the interrelated 
health factors or AD “exposomes” including diet, exercise, chronic stress, 
other environmental exposures, and AD development have been 
acknowledged (Biessels et al., 2006; Cui et al., 2018; De la Rosa et al., 
2020; Finch and Kulminski, 2019; McGrattan et al., 2019; Wild, 2012; 
Yang and Song, 2013). Environmental considerations also include 
investigating epigenetics and gene by environment (GxE) interactions 
by implementing GWAS to better understand genetic regulators of 
environmental effects and provide novel insights and targets for preci-
sion medicine solutions (Dhana et al., 2020; Eid et al., 2019; Hohman 
and Kaczorowski, 2020). The list of modifiable environmental factors 
that potentially impact AD progression continues to increase as research 
techniques and technology evolve to better survey large populations. 
Each of these factors and many others play a synergistic role and likely 
interact with genes to modify expression resulting in a certain pheno-
type. These factors and their effects are conditional in their role in AD 
development and progression (Chouliaras et al., 2010). For instance, 
aspects of weight control have been subjected to evaluation as certain 
diets and exercise regimes have proven to be beneficial to long term 
health and reduced disease incidence in later life. Reduced weight is 
often seen as a biomarker for AD that can occur even a decade before the 
onset of cognitive symptoms (Barrett-Connor et al., 1996; Buchman 
et al., 2005; Gillette-Guyonnet et al., 2000; Johnson et al., 2006; Wolf- 
Klein et al., 1992). When relating body mass index (BMI) and poly-
genetic risk scores calculated using all SNPs from a recent AD GWAS in 
humans, lower BMI and higher polygenic risk score significantly pre-
dicted conversion to AD (Moody et al., 2021). Conversely, early and 
mid-life increased weight and obesity, including that linked to high-fat/ 
high sugar Western diet consumption is associated with increased risk of 
AD and dementia (Naderali et al., 2009; Profenno et al., 2010; Tabassum 
et al., 2020). Overall, studying environmental effects on AD in human 
populations is extremely challenging due to lack of experimental control 
and wide amount of environmental variation humans are exposed to. 
This is further exacerbated because most studies rely on participant self- 
reporting and these results are often inaccurate and inconsistent 
(Cherbuin and Anstey, 2012; Otaegui-Arrazola et al., 2014; Rueda et al., 
2015; Singh et al., 2014; Yusufov et al., 2017). When these in-
consistencies are paired with the overwhelming amount of genetic di-
versity among humans, attempts to elucidate GxE interactions that 
influence AD are experimentally difficult. 
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1.4. Opportunity to complete longitudinal studies 
While sex and environmental factors contribute to the development 
and progression of AD, age is the greatest non-modifiable risk factor and 
the primary driver of developing AD. Disease risk dramatically increases 
after 60 years of age, but AD is not a normal aspect of aging, and not all 
individuals that exhibit hallmark AD pathology or symptoms develop 
AD (Hebert et al., 2013; Sonnen et al., 2011; Toepper, 2017). The 
definition of AD stages has evolved and become more dynamic as re-
searchers have determined that disease development varies between 
individuals. Initially, the stages of AD were defined at the autopsy of 
individuals that showed clinical signs of AD, like severe memory 
impairment, in life. Postmortem analysis of AD stages were ultimately 
based on the regional distribution, type, and density of brain pathology 
(Braak and Braak, 1991). Recently, preclinical and presymptomatic 
stages of AD were identified based on pathology in the post-mortem 
analysis of brains of cognitively unimpaired people. This suggests that 
disease onset can be defined differently depending on the evaluation of 
brain pathology versus clinical symptoms (Dubois et al., 2016; Hubbard 
et al., 1990; Sandberg et al., 2001; Villemagne et al., 2011). The dis-
covery that AD-related changes in the brain and pathology accumulation 
can begin potentially decades before the onset of clinical symptoms 
revealed potential confounds in previous AD cross-sectional studies that 
only analyzed individuals with MCI and AD versus “cognitively healthy 
control” subjects, as their control groups could have included pre-
symptomatic individuals with AD pathology (Aisen et al., 2017; Bennett 
et al., 2006; Driscoll and Troncoso, 2011; O’Brien et al., 2009; Price 
et al., 2009). In addition to identifying asymptomatic and prodromal 
phases of AD, recognition of hallmark AD pathology in cognitively intact 
individuals has also led to the classification of resilience and suscepti-
bility to AD-related decline (Aiello Bowles et al., 2019; Driscoll and 
Troncoso, 2011; Dumitrescu et al., 2020; Hampel et al., 2019a; Hohman 
et al., 2016; Negash et al., 2013; Neuner et al., 2017b; Stern et al., 2020; 
Walker and Herskowitz, 2020). Longitudinal efforts to identify bio-
markers and endophenotypes that allow for refined stage assessment are 
more crucial than ever as preclinical stages at which hallmark symptoms 
are not detectable may be an opportune period to engage in disease 
slowing or prevention measures. Additionally, understanding what 
factors shield resilient individuals versus those that cause others to be 
severely susceptible to AD development may provide key insight for 
treatment advancement (Seto et al., 2021). Longitudinal studies allow 
for the evaluation of AD as a continuum, but most of these studies only 
follow up with patients for an average of 1–2.5 years with limited 
repeated measures (Lawrence et al., 2017). Furthermore, only a few 
longitudinal human studies and designated aging cohorts such as the 
Religious Order Study, Mount Sinai Brain Bank study, or Rush Memory 
and Aging Project have the capacity to comprehensively assess disease 
progression (Bennett et al., 2018; De Jager et al., 2018; Wang et al., 
2018). Current human biomarkers measured longitudinally lack the 
sensitivity to identify early disease stages and disease subtypes (Cum-
mings, 2019). Ultimately, there is a need for model systems to better 
investigate the early stages of AD, AD causation, and to take a higher 
resolution look at changes in brain structure that occur with age and 
disease progression, especially during the stage when AD is clinically 
silent, and no overt symptoms are detected. 
1.5. The call for mouse models of AD 
Mouse models of AD offer the opportunity to study the disease 
longitudinally and in a more controlled manner to gain a better under-
standing how it manifests and progresses in humans. Mouse models are 
particularly advantageous because they can provide replicable genomes 
in controlled environments across relatively short lifespans, which can 
be implemented to address gaps in human research. Although many 
models are pathology-centric, there are currently over 205 existing AD 
mouse models that vary in their presentation of plaques, tangles, 
neuronal loss, gliosis, and synaptic dysfunction (Research Models: Alz-
heimer’s Disease, 2021). These models mostly consist of transgenic, 
knock-in (KI), or out (KO) modifications of single genes or a combination 
of genes associated with human AD, including APP, PSEN1/2, APOE, 
Trem2, BACE1, BACE2, MAPT and other GWAS-identified genes on 
various background strains (Drummond and Wisniewski, 2017). These 
models display AD-related phenotypes that can be accurately assessed 
and associated with disease progression (Götz et al., 2018; Granic et al., 
2010; Keene et al., 2016; Romberg et al., 2013). 
Recapitulating human AD (particularly LOAD) in mouse models has 
proven difficult; therefore, choosing the appropriate AD model mouse 
population is crucial since many models selectively display different 
aspects of the disease and mouse findings have not translated well to 
humans (Cao et al., 2018; Cummings et al., 2014; Franco and Cedazo- 
Minguez, 2014; Jankowsky and Zheng, 2017; King, 2018). A reason 
for this lack of translatability is that most traditional mouse models of 
AD are made using genetically identical mice and lack the genetic di-
versity present in humans (Moore et al., 2020; Onos et al., 2016). While 
traditional mouse models, which were needed, timely, and useful for 
their era, were a great starting point for using model systems to study 
AD, it is now apparent that they are not the most translationally relevant 
models available and that genetic diversity is crucial for both the 
development of models and AD mouse research moving forward. 
1.6. Translatable mouse models 
To combat the limitations of traditional mouse models, mouse 
models with diverse genetic backgrounds have recently been generated 
and utilized to study AD in a more translational manner (Neff, 2019; 
Neuner et al., 2019a; Neuner et al., 2017a; Neuner et al., 2020; 
O’Connell et al., 2019; Onos et al., 2019; Yang et al., 2021). For 
example, genetic diversity can be added to standard AD mouse models 
with the incorporation of BXD recombinant inbred strains. The BXD 
panel is the product of independent advanced intercrosses between 
C57BL/6 J (B6) and DBA/2 J (D2) progenitor strains (Peirce et al., 
2004). Application of the BXD panel is conducive to systems biology 
approaches, as the panel has a genetically defined diverse background 
that can be easily manipulated in a reproducible manner. The BXD 
family segregates at over five million common genetic variants and more 
than 140 strains are currently available (Wang et al., 2016b). These 
additional BXD strains offer greater mapping power and the ability to 
refine mapping precision (Ashbrook et al., 2021). The BXD population 
has been highly characterized in a variety of studies, creating a wealth of 
phenotyping and omics data (Studies Involving BXD RI Panel, 2021). 
The BXD population was demonstrated to be a valuable resource for 
creating the first mouse model that better recapitulates the complex 
heterogeneity of genetic, molecular and cognitive features of human 
cognitive aging and AD (Neuner et al., 2016; Neuner et al., 2019a; 
Neuner et al., 2017a). The AD-BXD population was generated by 
crossing the commonly used B6-5XFAD AD mouse model with strains 
from the BXD panel. The AD-BXD panel offers all of the advantages of 
the BXD population in an AD mouse model, and, importantly, this model 
mouse panel exhibits a range in age at onset and variation in AD 
symptom severity that is comparable to LOAD in human populations 
(Neuner et al., 2019b; Neuner et al., 2017a; Ryman et al., 2014). This 
panel also exhibits a high degree of genetic and transcriptomic overlap 
with human LOAD (Heuer et al., 2020; Lambert et al., 2013; Neuner 
et al., 2019a; Neuner et al., 2017a; Wan et al., 2020). Ultimately, 
genetically diverse panels like the AD-BXD that recapitulate multiple 
facets of AD offer the scientific community a more applicable model 
system to study the genetic mechanisms that modify the onset and 
progression of AD across a population. 
1.7. Use of systems biology to better understand the complexity of AD 
Following the advent of the amyloid beta cascade hypothesis as a 
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proposed cause of AD, numerous clinical trials targeted the reduction 
and prevention of amyloid plaques in an attempt to lessen the symptoms 
and progression of AD (Hardy and Selkoe, 2002; Hardy and Higgins, 
1992; Lemere and Masliah, 2010; Reitz, 2012; Schneider et al., 2014). 
None of these trials successfully alleviated pathology progression, neu-
rodegeneration, or major long-term symptoms, therefore forcing the 
research community to acknowledge the immense complexity of AD 
(2020 Alzheimer’s Disease Facts and Figures, 2020; Cao et al., 2018; 
Chen et al., 2017; Langley, 2014). Since this realization, AD researchers 
more commonly utilize systems biology approaches to better understand 
interactions between various systems in the human body and how they 
impact, and are impacted by, AD (Alberghina and Colangelo, 2006; 
Castrillo et al., 2018; Lista et al., 2016; Rosario et al., 2020). The fact 
that we observe similar disease phenotypes despite differences in genetic 
modulators (ex: between FAD and LOAD) suggests that the different 
causes of disease are not unrelated but are rather likely due to dysre-
gulation of similar biological networks. Systems biology is a field of 
study built on the organization of sub fields responsible for complex 
behaviors and outcomes, including identifying the links between genes 
and behavior according to the net interactions of varying components 
(Liu, 2005). Modern systems biology involves interdisciplinary, data- 
driven approaches with a greater focus on untangling complex in-
teractions between genetic, epigenetic, physiological, and environ-
mental factors at multiple system levels within an organism. Recent 
advancements in biotechnology have made this approach more feasible 
and enable genome-wide and multi-omics studies to be conducted with 
multiple disease-mediated factors (Heuer et al., 2020; Lam et al., 2020). 
Systems biology puts a greater emphasis on connection, integration and 
modularity of genes and pathways rather than single causal gene pre-
dictions. This approach is crucial for the study of complex diseases like 
AD because their cures require multifaceted treatments tested in diverse 
and translatable models. Development of such a treatment requires the 
implementation and integration of transcriptomics, proteomics, 
metabolomics, genomics, epigenomics, lipidomics, and/or micro-
biomics to gain a wholistic understanding of complex systems across 
representative populations (Fig. 1) (Ahn et al., 2006; Ehrenberg et al., 
Fig. 1. Analyzing the Interacting Components of System Biology in the Study of Alzheimer’s Disease (A) The study of systems biology and the discovery of genotype 
to phenotype relationships involves the interaction of multiple levels: 1. biological systems, 2. environmental perturbations, 3. biological scales, and 4. clinical traits. 
(B) Because AD is a complex disease, modeling of biological networks is required to test and discover the relationship between factors and mechanisms. Combinations 
of single or multiple factors from each biological and environmental scale (A:1–4) should be included in models to determine the correlation between data types and 
resulting clinical outcomes. (B) shows a hypothetical model of how the factors from (A) could interact. Each factor can impact others with varying weights of in-
fluence indicated by the width of the arrows. (Created with BioRender.com). 
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Table 1 
Neuroimaging in AD: modalities and typical findings.  
Imaging modality Brain measurement Measured changes with relation to AD Citations 
F-fluorodeoxyglucose 
(FDG) PET  
• FDG compound uptake from neurons in the 
brain is analogous to glucose uptake. Glucose is 
the main energy substrate of the brain  
• Glucose uptake and brain metabolism is related 
to neuronal and synaptic function  
• Glucose hypometabolism is commonly observed 
in the parietotemporal association cortices, 
posterior cingulate cortex, and the precuneus 
bilateral temporoparietal.  
• Hypometabolism highly correlates with the 
pathological diagnosis of AD 
(Brown et al., 2014; De Santi et al., 2001;  
Foster et al., 1983; Foster et al., 2007;  
Hoffman et al., 2000; Marcus et al., 2014;  
Mosconi, 2005; Silverman et al., 2001) 
Amyloid PET  • Tracer uptake used to identify Aβ plaque 
accumulation  
• Identify the presence, location, and spread of 
amyloid throughout the brain  
• Higher tracer retention found in the frontal 
cortex parietal cortex, corpus striatum, 
temporal, and occipital cortex  
• Not conclusive as a diagnostic factor since 
amyloid accumulation can greatly vary among 
those with and without AD 
(Agdeppa et al., 2001; Cselényi et al., 2012;  
Kudo et al., 2007; Landau et al., 2014;  
Ossenkoppele et al., 2012; Rinne et al., 
2012; Rowe et al., 2008; Verhoeff et al., 
2004; Wong et al., 2010) 
Tau PET  • In vivo tracers used to identify tau deposition  
• Tracers bind to aggregated intracellular and 
extracellular neurofibrillary tangles  
• Tracer retention is higher in those with AD  
• Accumulation commonly found to spread from 
inner regions like the medial temporal lobe 
outward towards the hippocampus, entorhinal 
cortex, and fusiform gyrus and lastly into the 
neocortex indicative of disease progression  
• Tracer binding is negatively correlated with 
cognitive performance 
(Brier et al., 2016; Cho et al., 2016; Jack Jr. 
et al., 2018; Leuzy et al., 2019; Maass et al., 
2017; Mueller et al., 2020; Scholl et al., 
2019; Wang et al., 2016a) 
Synaptic vesicle 
glycoprotein 2A 
(SV2A) PET  
• SV2A is ubiquitously expressed in essentially 
all presynaptic vesicles  
• Imaging of radioligand tracers to detect SV2A  
• Detection is used as a biomarker for synaptic 
density  
• Reduced tracer uptake indicates synapse loss in 
the hippocampus and entorhinal cortex, as well 
as the parahippocampal cortex, amygdala, 
lateral temporal cortex, prefrontal cortex, 
posterior cingulate cortex (PCC)/precuneus, 
lateral parietal cortex, and pericentral cortex  
• Negative relationship between global amyloid 
deposition and SV2A binding  
• Positive correlation of hippocampal SV2A 
binding associated with episodic memory 
(Bastin et al., 2020; Cai et al., 2019; Chen 
et al., 2018b; Finnema et al., 2018; Mecca 
et al., 2020; O’Dell et al., 2021) 
Translocator Protein-18 
kDa (TSPO) PET  
• TSPO is a transmembrane domain protein 
expressed on the outer mitochondrial 
membrane of microglia  
• Tracer binding is a measure of microglial 
density and neuroinflammation  
• TPSO expression is upregulated in activated 
microglia and astrocytes  
• Increased TSPO binding is found in regions with 
high pathology including the hippocampus, 
striatum, lateral temporal, parietal, anterior 
cingulate cortex, and medial prefrontal cortex  
• Increased TSPO tracer binding is associated 
with greater glial activation and cognitive 
impairment 
(Edison et al., 2008; Kreisl et al., 2016;  
Kreisl et al., 2013; Lagarde et al., 2018;  
Mirzaei et al., 2016; Tournier et al., 2020;  
Yasuno et al., 2008) 
Structural MRI  • Measurement of gray and white matter 
integrity  
• Regional volumes assess macrostructural 
atrophy Identify patterns of neurodegeneration  
• Increased atrophy associated with greater risk of 
converting to Alzheimer’s disease (AD) in 
individuals with mild cognitive impairment 
(MCI)  
• Hippocampal and medial temporal lobe volume 
are related to cognitive score as diagnostic 
factors 
(Cardenas et al., 2011; Hua et al., 2008;  
Plant et al., 2010; Ridha et al., 2008;  
Spulber et al., 2013; Vemuri and Jack, 
2010) 
Functional MRI- resting 
state or tasks 
dependent  
• Synaptic activity evaluated by changed in 
blood oxygen level dependent (BOLD) MR 
signal  
• Measurement of functional integrity of brain 
networks  
• Regional functional connectivity can be 
assessed at rest or a during relevant cognitive 
tasks  
• Detection of brain regions associated with 
memory task performance and how connections 
change with age and disease status  
• Hypoactivity is noted in some areas while 
hyperactivity is seen in others; hyperactivity 
might represent a compensatory mechanism in 
the setting of early AD pathology 
Hyperactivity in regions such as the 
hippocampus or medial temporal lobe are 
viewed as a biomarker for conversion from MCI 
to AD 
(Bookheimer et al., 2000; Dickerson and 
Sperling, 2008; Logothetis et al., 2001;  
Machulda et al., 2003; Ogawa et al., 1990;  
Rombouts et al., 2000; Sperling et al., 2010;  
Vemuri et al., 2012) 
Diffusion Tensor Imaging 
(DTI)  
• Derive voxel-based measures of the movement 
of water molecules in the brain to assess tracts 
and predict structural connectivity  
• Measurement of white matter integrity and 
microstructural damage  
• Common measures: fractional anisotropy (FA): 
degree of directionality of water diffusion, 
mean diffusivity (MD): mean water diffusion 
rate, axial diffusivity (AxD): rate of water 
diffusion along the longitudinal axis, radial 
diffusivity (RD): rate of diffusion along the 
perpendicular axis, free water (FW)  
• FA and MD provide information about changes 
to barriers to diffusion 
Increased AxD is associated with axonal 
degeneration and increased RD has been linked 
to demyelination  
• AD is associated with reduced white matter 
integrity (low FA, high MD, AxD, and RD)  
• Increased free water measure is associated with 
AD-related neuroinflammation 
Decreased FA and increased RD is commonly 
seen in white matter structures (corpus cal-
losum, anterior commissure, fimbria, and in-
ternal capsule) 
(Alexander et al., 2007; Colon-Perez et al., 
2019; Febo et al., 2020; Harrison et al., 
2020; Mayo et al., 2019; Ofori et al., 2019;  
Ouyang et al., 2015; Sahara et al., 2014)  
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2003; Hiesinger and Hassan, 2005; Kirschner, 2005; Kitano, 2002b; Liu, 
2005; Weston and Hood, 2004). Ultimately, the harmonization of mul-
tiple data types across various body systems will provide a better 
method of surveying the many components involved in the development 
and progression of AD. 
Expanding beyond correlational analyses, systems biology has also 
benefitted from the advent of causal inference methods in establishing 
links between genotype and phenotypes, and all systems in between 
(Haas et al., 2016; Shen et al., 2020). Adopting this approach to studying 
AD, national and international human and mouse focused consortia 
were launched to integrate data types to gain a better understanding of 
the brain and the changes that occur in response to onset of AD. Ini-
tiatives by The Alzheimer’s Association, Human Brain Project, and 
Foundation for the National Institutes of Health Biomarkers Consortium 
have all taken steps to implement systems biology approaches to 
studying AD. The National Institute on Aging’s AD Translational 
Research also established programs including Accelerating Medicines 
Partnership- AD (AMP-AD), Molecular Mechanisms of the Vascular 
Etiology of Alzheimer’s Disease (M2OVE-AD), Translational Center for 
Model Development and Evaluation for Late Onset Alzheimer’s Disease 
(MODEL-AD), Cognitive Resilience to Alzheimer’s Disease (Resilience- 
AD), and Neuropsychiatric Symptoms in Alzheimer’s Disease (Psych- 
AD), which are dedicated to uncovering the multifaceted roots of AD. 
Furthermore, there are initiatives dedicated to including specific 
methods such as the Alzheimer’s Disease. 
2. AD diagnosis: from the lab to the clinic 
2.1. Imaging modalities to assess AD 
With advancements in technology, imaging modalities have recently 
become a highly effective method for identifying and monitoring age- 
and AD-related structural and functional changes in the brain. Modern 
forms of microscopy implemented in mouse models allows for better 
spatial and temporal resolution images than ever before. Cross sectional 
whole 2D and 3D brain mapping at different disease stages and ages can 
now be used to identify regional vulnerability to pathology or changes in 
specific cell types, especially in deeper brain regions difficult to access in 
vivo (Chen et al., 2018a; Gail Canter et al., 2019; Lichtenegger et al., 
2018; Munoz-Castaneda et al., 2021; Whitesell et al., 2019). These 
techniques can also be applied in transgenic mice or those injected with 
specific tracers, such as those used to label active neurons during a 
memory task, to establish connections between regional activation and 
behavior (Roy et al., 2019; Vetere et al., 2017). While the application of 
imaging modalities can be readily applied in mouse models, currently 
these methods have been most thoroughly investigated in humans. 
Improvements in in vivo imaging resolution and accessibility now 
allow for human AD diagnoses prior to pathology and atrophy detection 
at death. The most commonly utilized methods include the minimally- 
invasive magnetic resonance imaging (MRI) and positron emission to-
mography (PET), which give researchers and medical teams a better 
look at the active brain to then make a diagnosis and assess disease state 
(Marcus et al., 2014; Márquez and Yassa, 2019; Scheltens, 2009; Smith, 
2002). Various imaging approaches (outlined in Table 1) allow for the 
detection of neural connectivity deficits, the presence and progression of 
pathology, tissue atrophy, and even metabolic measures. These mea-
sures can then aid in the discovery of brain regions vulnerable to specific 
measures collected during each imaging processes (Johnson et al., 2012; 
Pini et al., 2016; Reiman and Jagust, 2012; Teipel et al., 2015; Young 
et al., 2020). Since many features of AD can be detected non-invasively, 
imaging can be readily used to increases the accuracy of clinical as-
sessments and monitored longitudinally (Jack et al., 2013; Jack Jr. et al., 
2010; Jagust et al., 2006; Karow et al., 2010; Oishi et al., 2011; Ota et al., 
2015; Zhang et al., 2011). Identification of predictive AD biomarkers 
and patterns in structural and functional changes can be used as endo-
phenotypes to relate to other aspects of systems biology to address the 
Table 2 
Tools for multi-omics integration, viewing, and analysis.Can Table 2 and 3 be 
widen and displayed as one data frame like Table 1 is formatted in the PDF? Each 
table is currently split in the proof.  
Tools to view and/or 
analyze multi-omics 
datasets 
Purpose of tool Platform Citation 
Multi-Omics Factor 
Analysis (MOFA)  
• Statistical method for 
integrating multiple 
modalities of omics 
data in an 
unsupervised fashion  
• MOFA disentangles to 
what extent each 
factor is unique to a 
single data modality or 







et al., 2018) 
MixOmics  • Classify or 
discriminate sample 
groups, to identify the 
most discriminant 
subset of biological 
features, and to predict 
the class of new 
samples 
R Package (Rohart 




method (MINT)  
• Integrates 








R package (Rohart 








• A multi-omics method 
that simultaneously 
identifies key omics 
variables (mRNA, 
miRNA, CpGs, pro-
teins, metabolites etc.) 




• DIABLO maximizes the 




R package (Singh et al., 
2019) 
Similarity network 
fusion (SNF)  
• Similarity network 
fusion (SNF) 
constructs networks of 
samples for each 
available data type 
and then efficiently 
fusing these into one 
network that 
represents the full 
spectrum of 
underlying data  
• Uses similarity 
networks of samples as 
a basis for integration 
R and 
Matlab Code 
(Wang et al., 
2014) 
Paintomics  • Integrative 
visualization of 
multiple omic datasets 
onto KEGG pathways 
Web-based (Hernandez- 
de-Diego 
et al., 2018) 
3Omics  • Visualize and rapidly 
integrate multiple 
human inter- or intra- 
transcriptomic, prote-
omic, and metab-




Web-based (Kuo et al., 
2013) 
(continued on next page) 
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biological mechanisms driving AD progression. This integration of im-
aging and omics data collected with systems biology approaches, or 
neuroimaging-omics, is an emerging field dedicated to characterizing 
genetic, biological, and phenotypic clusters which can then be used to 
develop methods for detecting, treating, or possibly preventing disease 
development with early intervention (Hampel et al., 2021; Mroczek 
et al., 2021; Richiardi et al., 2015). Many neuroimaging-omics studies 
employ machine learning frameworks to multi-modal data to predict 
potential AD risk in MCI and pre-symptomatic patients (Basaia et al., 
2019; Khanna et al., 2018; Scelsi et al., 2018). Neuroimaging-omics has 
the potential to untangle genetic mutations, gene expression patterns, 
and protein-protein interactions and determine how they are linked to 
large-scale structural and functional network deficits and disease 
manifestation. 
2.2. Technology’s contribution to enhancing the imaging field and AD 
experiments 
Disease characterization and identification of AD biomarkers with 
imaging analyses have significantly progressed due with advances in 
modern technology. Methods to accommodate the large datasets 
required to power systems biology experiments are being streamlined to 
reduce the significant subjectivity and time commitment previously 
required to obtain and interpret results from imaging studies. Using 
automated pipelines that incorporate standard brain atlases, like the 
Allen Brain Atlas Common Coordinate Frame, comprehensive connec-
tivity maps are being developed to better understand mammalian brain 
circuitry (Denk et al., 2012; Wang et al., 2020). The Mouse Brain 
Table 2 (continued ) 
Tools to view and/or 
analyze multi-omics 
datasets 
Purpose of tool Platform Citation 
pathway enrichment, 
and GO (Gene 
Ontology) enrichment 
analysis methods 
JIVE  • Quantifies the amount 
of joint variation 
between data types, 
reduces the 
dimensionality of the 
data, and provides 
new directions for the 
visual exploration of 
joint and individual 
structure 
R Package (Lock et al., 
2013) 
MiBiOmics  • Enables the 
exploration, 
integration, analysis 
and visualization of up 
to three omics 
datasets. Through the 
primary exploration of 
a dataset, the inference 
of biological networks 
and the extraction of 
multi-omics associated 
features, the applica-
tion provides a ready- 
to-use analysis pipe-
line to interactively 
explore sources of 
variability and vari-
ables of interest in a 
given biological data-
set, as well as associa-
tions between multi- 
omics features in 
multi-scale studies 






• Explores omics- 
specific learning and 
cross-omics correla-
tion learning for effec-
tive multi-omics data 
classification  
• Supervised multi- 
omics integrative 
method that utilizes 
graph convolution 
networks for omics 
data learning to 
perform effective class 











• Fuses the gene co- 
expression network 
analysis, deep learning 
techniques, feature se-
lection, Cox propor-













• Algorithm for multi- 
omics clustering  




R Package (Rappoport 
and Shamir, 
2019) 
Galaxy  • Enables users to 
perform integrative 
omics analyses by 
providing a unified, 
web-based interface 
for obtaining genomic 
Web-based (Boekel 
et al., 2015)  
Table 2 (continued ) 
Tools to view and/or 
analyze multi-omics 
datasets 
Purpose of tool Platform Citation 
data and applying 
computational tools to 
analyze the data 
Argonaut  • Code-free platform for 
creating customizable, 
interactive data- 
hosting websites  
• Carries out real-time 
statistical analyses of 
the data. Collaborating 
researchers worldwide 
can explore the results, 
visualized through 
popular plots, and 









• Provides researchers 




data from multiple 
brain regions of AD 
patients 








• A comprehensive 




various types of het-
erogeneous biological 
networks, and clinical 
databases for target 
identification and 
development of effec-
tive prevention and 
treatment for AD. 
Web-based (Zhou et al., 
2021)  
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Architecture Project, Allen Mouse Brain Connectivity Atlas project, and 
Mouse Connectome Project each have taken on the challenge of sys-
tematically mapping the spatial profiles and the connectivity of 
neuronal populations throughout the brain (Bohland et al., 2009; Furth 
et al., 2018; Helmstaedter and Mitra, 2012; Mitra, 2014; Oh et al., 2014; 
Osten and Margrie, 2013). Through these investigations and others, a 
myriad of image analysis pipelines been created to investigate links 
between regional brain activity, gene expression, and behavior (Feng 
et al., 2015; Freeman et al., 2014; Ji et al., 2014; Ng et al., 2009; Renier 
et al., 2016). Computational biologists are also creating these workflows 
to increase reproducibility, make machine learning and automated im-
aging processing methods more accessible to biologists, and allow high- 
throughput processing across the brain. Semi-automatic registration 
methods with all parameters shared with the scientific community 
encourage non-experts to analyze high resolution MRI, DTI, histology, 
and two-photon tomography results (Anderson et al., 2019; Budin et al., 
2013; Esteban et al., 2019; Furth et al., 2018; Liu et al., 2020; Niedworok 
et al., 2016; Pagani et al., 2016; Pallast et al., 2019; von Chamier et al., 
2021; Winnubst et al., 2019; Yates et al., 2019). The recent combination 
of neuroimaging, computer-aided diagnosis techniques, and machine 
learning methods (e.g. linear discriminant, logistic regression, random 
forest, and neural networks analyses) have allowed researchers and 
clinicians alike to establish data-driven AD classification standards 
(Basheera and Sai Ram, 2019; Dimitriadis et al., 2018; Leandrou et al., 
2018; Liu et al., 2019; Wen et al., 2020). Integrating multi-omics data is 
also increasingly more feasible and approachable for biologists with the 
development and improvement of omics technologies aimed at aiding 
the combination and analysis of multiple data types (outlined in 
Table 2). The availability and application of current tools have also been 
thoroughly reviewed (Adil et al., 2021; Graw et al., 2021; Huang et al., 
2017; Krassowski et al., 2020; Ma et al., 2020; Misra et al., 2018; Nicora 
et al., 2020; Subramanian et al., 2020; Worheide et al., 2021). One noted 
drawback of many of the mentioned tools in these reviews is that they do 
not necessarily have the capacity to incorporate imaging or behavioral 
phenotyping data in addition to the varying omics data. 
Moreover, systematic machine-learning assisted approaches to im-
aging are no longer exclusively restricted to post-processing analyses but 
also to assist in experimental parameter design to enhance microscopy 
techniques and output. This field of “smart microscopy” integrates 
feedback from the microscope to adjust computer assisted imaging al-
gorithms to optimize sample coverage, extend the field of view, or 
improve spatial resolution and signal strength (Durand et al., 2018; He 
and Huisken, 2020; Mahecic et al., 2020; Royer et al., 2016). Re-
searchers are now equipped with the ability to map regional behavior- 
induced brain activity, which can prove to be highly valuable in deter-
mining which regions, cell types, and circuits are most heavily affected 
by AD and in response to certain tasks assessing clinical symptoms. 
3. Incorporating imaging outcomes in mouse systems biology 
studies to predict cognitive outcomes and AD progression 
Imaging approaches have proven to be an invaluable resource to the 
field of AD research in terms of assessing changes in neuroanatomy and 
neural connections; however, attempts to link imaging measures and 
multi-omics data to phenotypic disruptions associated with AD in model 
systems remain scarce. Furthermore, many of these studies are not suf-
ficiently powered with the number of mice needed for the application of 
systems biology approaches. Although current approaches for assessing 
the brain using imaging methods do not allow for the discovery of the 
mechanisms and interacting relationships driving these changes, efforts 
to link imaging measures to cognitive outcomes are underway. Imaging 
modalities used to visually assess disease progression provides re-
searchers with an intermediate to model the relationship between 
structure and function in model mice. 
Depending on the study of interest, imaging data is independently 
compared to or directly correlated with cognitive functioning within 
cohorts of model mice to assess functional or connectivity properties in 
relation to level of AD-related decline. MRI studies using a variety of 
model mouse lines have described changes in regional neuronal activity, 
differences in volume, and structural integrity to identify vulnerable 
brain regions. For example, manganese enhanced MRI (MEMRI) can be 
used to map complex brain circuits involved in spatial memory. 
Decrease in MEMRI signal after Morris water maze (MWM) testing 
corroborates the reduced neuronal activity in memory circuits typically 
seen in old AD mice (Badea et al., 2019). Similarly, identification of 
regional atrophy in relation to behavioral outcomes can also be 
explored. Among several types of AD model populations, atrophy at the 
whole brain level, as well as memory associated areas like the hippo-
campus, entorhinal cortex, amygdala, and temporal association cortex 
has been observed in mice with reduced spatial memory (Liang et al., 
2017; Tang et al., 2016). Depending on the mouse line used, these 
changes in brain structure and connectivity can be observed as early as 
2 months of age, preceding the onset of amyloid deposition and severe 
cognitive decline (Badea et al., 2010; Falangola et al., 2007). Studies 
that validate changes in MRI volume with histology provide further 
evidence that MRI outcomes that identify regional atrophy correspond 
to reductions in neuron counts and poor spatial memory performance 
(Badea et al., 2019). However, currently there is a lack of consensus 
regarding regional atrophy or enlargement in mice and how this dif-
ference relates to reduced cognitive performance on memory tasks and 
certain ages (Badhwar et al., 2013; Maheswaran et al., 2009). 
Brain metabolism has also been related to cognitive performance 
using fluorodeoxyglucose (FDG) PET. Correlation analyses have showed 
that hippocampal standardized uptake values were significantly corre-
lated with MWM parameters at the symptomatic-AD stage (Li et al., 
2016). Aged Tg4–42 transgenic animals with compromised spatial 
memory also display neuron loss, regional volume decreases, and 
hypometabolism – as measured by reduced tracer uptake, in the hip-
pocampus, forebrain, hypothalamus, amygdala and midbrain (Bouter 
et al., 2018). Likewise, neuroinflammatory response supported by his-
tology shows significant effects of age and genotype on translocator 
protein (TPSO) tracer uptake in the hippocampus and cortex exist in 
APPswe × PS1Δe9 transgenic mice, but their working memory perfor-
mance greatly varied with age (Chaney et al., 2018). Serial PET mea-
sures of TSPO and amyloid with terminal spatial memory assessment in 
PS2APP model mice, followed by immunohistochemical analyses of 
microglia, amyloid, and synaptic density revealed that high microglial 
activation at the onset of amyloidosis (8 m of age) predicts better 
cognitive performance in PS2APP mice at follow-up 5 months later (13 
m of age), when amyloid pathology is extensive. Highest TSPO PET 
signal was found in areas associated with spatial learning and negatively 
correlated with Iba1 immunostaining (Focke et al., 2019). Conducting 
multi-modal analyses help in defining a more precise relationship be-
tween cognitive outcomes and morphological changes of the brain. 
Moreover, in vivo 2-photon calcium imaging evaluation of APP23xPS45 
mice has shown neuronal hyperactivity near Aβ plaques. With this in-
formation, a correlation was observed between the formation of amyloid 
plaques, the appearance of hyperactive neurons, and the age-related 
impairment of the spatial learning capability (Busche et al., 2008). 
Further studies investigating neuronal hyperactivity revealed that the 
function of hippocampal neurons is altered long before that of cortical 
neurons (Busche et al., 2012). 
Moving beyond comparisons between imaging measures and 
behavior, the field is turning towards probing neuroimaging-omics in-
teractions in mice (Liu and Liu, 2011). For example, genetic mapping of 
phenotypes derived from imaging data using the BXD panel revealed 
significant quantitative trait loci associated with traits such as hippo-
campal volume (Ashbrook et al., 2014). Cellular and pathology loads 
calculated using brain-wide immunohistochemistry can also be inte-
grated with bulk RNA sequencing data to evaluate associations between 
regional cell counts, gene expression, and biological, molecular, or 
cellular pathways (Gurdon et al., 2020). Moreover, spatial 
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transcriptomics offers the ability to survey regional transcriptional 
changes in mice. Using this method, molecular changes occurring in 
cells in the vicinity of amyloid plaques can be investigated by charac-
terizing gene co-expression networks that appeared to be highly 
responsive to Aβ deposition. The plaque-induced genes (PIGs) are a 
response in multiple cell types across the brain and are implicated to 
involve the complement system, oxidative stress, lysosomes, and 
inflammation, all of which are more prominent in the later phases of the 
disease (Chen et al., 2020). Furthermore, regions vulnerable to AD- 
related changes can be honed in on to uncover molecular targets, such 
as those that may contribute to early hippocampal synaptic deficits and 
olfactory dysfunction in AD mice (Navarro et al., 2020). Ultimately, 
these studies and many more incorporate select aspects of systems 
biology and imaging methods to tie together genotype and phenotype; 
however, many studies that employ imaging techniques are lacking 
complementary omics and behavioral data to achieve a comprehensive 
analysis of brain changes with AD. 
4. Refining AD diagnosis with the establishment of subtypes 
There is a novel opportunity to more optimally segregate AD into 
subtypes by combining in vivo depictions of AD progression (collected 
via imaging) with omics data. By refining AD diagnoses beyond typical, 
resilient, or susceptible, researchers will be able to better understand the 
heterogeneity of AD symptoms, manifestation, and causal influences, 
which will be crucial for executing precision medicine approaches and 
developing successful treatments for AD. 
Noticing that not all human AD cases neatly follow Braak staging, 
researchers have begun to classify subtypes of AD based on the detection 
of regional pathology in conjunction with clinical data. Early ap-
proaches to tackle this discrepancy evaluated cases that had severe 
Braak scores and subdivided them by NFT density and location. Three 
postmortem classifications of typical, hippocampal sparing, or limbic 
predominant AD were derived and further characterized in terms of 
prevalence in the experimental population, age demographics, and rate 
of cognitive decline exhibited within each subtype (Murray et al., 2011). 
Building on this concept, tau-PET in combination with demographic 
data, clinical outcome measures, and APOE e4 frequency was used to 
refine these subtypes into pathology driven region-specific subtypes 
prior to death (Armstrong and Wood, 1994; Charil et al., 2019; Ossen-
koppele et al., 2020; Vogel et al., 2021; Whitwell et al., 2018). Recent 
approaches that further evaluated these subtypes found that there is 
largely a consensus between subtyping based on tau-PET and regional 
atrophy measured using structural MRI methods (Kolanko and Malho-
tra, 2018; Park et al., 2017; Ten Kate et al., 2018). Differential patterns 
of brain atrophy revealed general and reproducible subtypes of AD, 
including typical, limbic-predominant, hippocampal-sparing, mild at-
rophy, and no atrophy (Byun et al., 2015; Ferreira et al., 2017; Kark-
kainen et al., 2020; Whitwell et al., 2012; Zhang et al., 2016). FDG-PET 
has been implemented as an additional measure correlated with regional 
atrophy to enhance subtype specificity (Huang et al., 2017; Levin et al., 
2021). Such studies link individuals with hippocampal sparing AD, 
greater global hypometabolism, and reduced executive functioning 
(Risacher et al., 2017). Importantly, while these classifications are 
beneficial for appreciating the heterogeneity of AD, there are method-
ological inconsistencies, and unbiased, multi-modal approaches are 
needed to better explore disease mechanism (Mohanty et al., 2020). 
With the capacity to combine imaging data with genetic information, 
unique subtypes rooted in clinical phenotypes, omics, and known re-
gions vulnerable to dysregulation can be classified. Understanding 
subtypes of AD can allow researchers to develop targeted treatments and 
clinicians to better predict disease course in patients. By clustering 
differentially expressed genes and conducting weighted network ana-
lyses, tau-mediated neurodegeneration, amyloid-β neuroinflammation, 
Fig. 2. Utility of animal models and systems biology approaches for precision medicine solutions (A) Using a translationally relevant and diverse model mouse 
population, (B) a vast amount of longitudinal imaging and omics data can and has been collected to develop predictive networks and (C) identify drivers of resilience. 
(D) These identified modulators can guide the classification of AD subtypes. Subtypes reflect a pattern or prevalence of the collected imaging and omics endo-
phenotypes measures. Single or groups of mouse strains can then be classified into these subtypes based on the display of similar traits, and if available, compared to 
established human subtypes. Mice sorted into these subtypes can then directly enter the precision medicine discovery drug cycle. (E) We recently tested AD-BXD 
strains against established human AD subtypes to define human relevant subtypes from hippocampal RNAseq data. (F) Mouse subtypes that appropriately align 
with human subtypes will then proceed through the pipeline. In vitro models that recapitulate the cellular and molecular profiles of each subtype can be create and 
implemented to conduct compound screens. Measures of neurodegeneration, synapse number and type, axonal degeneration, and neuron excitability can be 
quantified to assess the result of each compound on the model system. (G) The efficacy of a select compound’s ability to alter disease course in mice of certain 
subtypes can then be assessed in vivo with cognitive phenotyping. Overall outcomes of this pipeline will enable precision medicine solutions to be identified per 
disease subtype and then potentially applied in clinical trials for humans or to refine the selection of mouse strains in future discovery trials. (Created with BioR 
ender.com). 
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Table 3 
General multi-omics and AD specific data portals and platforms.  
Data portal Portal description Citation 
OpenNeuro  • A free and open platform for 
validating and sharing Brain 
Imaging Data Structure 
(BID)S-compliant MRI, PET, 
MEG, EEG, and iEEG data 
https://openneuro. 
org/ 
Enhancing Neuro Imaging 
Genetics Through Meta- 
Analysis (ENIGMA)  
• Consortium to bring 
together researchers in 
imaging genomics to 
understand brain structure, 
function, and disease, based 




Encyclopedia of DNA 
Elements (ENCODE)  
• A comprehensive list of 
functional elements in the 
human genome, including 
elements that act at the 
protein and RNA levels, and 
regulatory elements that 
control cells and 
circumstances in which a 
gene is active 
https://www.enco 
deproject.org/ 
Synapse by Sage 
Bionetworks  
• A collaborative, open-source 
research platform that al-
lows teams to share omics, 
imaging, and phenotypic 
data, track analyses, and 
collaborate 
The AD Knowledge Portal, 
Brain Somatic Mosaicism 
Network Portal, Cancer 
Complexity Knowledge Portal, 
dHealth Digital Health 
Knowledge Portal, 
Neurofibromatosis Portal, and 
Psychencode Knowledge Portal 








• Collection of multi-omics 
data, methods, and results 
generated within the 
network are distributed 
under FAIR Distribution of 
data principles from: Accel-
erating Medicines Partner-
ship in Alzheimer’s Disease 
(AMP-AD), Molecular 
Mechanisms of the Vascular 
Etiology of AD (M2OVE-AD) 
program, Resilience-AD 
program; (3) the Psych-AD 
program, Translational Cen-
ter for Model Development 
and Evaluation for Late 





AGORA  • Hosts evidence for whether 
or not genes are associated 
with AD. Agora also contains 
a list of close to 100 nascent 
drug targets for AD that 
were nominated by AD 
researchers 
Partnered with NIH-led Accel-
erating Medicines Partnership 
– Alzheimer’s Disease (AMP- 
AD) Target Discovery and Pre-




Alzheimer’s Disease and 
Healthy Aging Data 
Portal  
• Provides access to national 
and state level CDC data on a 
range of key indicators of 







• A single-cell RNA-Seq data-
base for Alzheimer’s Disease 
scREAD covers 73 datasets 
https://bmbls.bmi. 
osumc.edu/scread/  
Table 3 (continued ) 
Data portal Portal description Citation 
Alzheimer’s disease 
(scREAD) 
from 16 studies, 10 brain 




• ADNI researchers collect, 
validate and utilize data, 
including MRI and PET 
images, genetics, cognitive 
tests, CSF and blood 
biomarkers as predictors of 
the disease. Study resources 
and data from AD patients, 
mild cognitive impairment 
subjects, and elderly 
controls in the North 




The National Institute on 
Aging Genetics of 
Alzheimer’s Disease 
Data Storage Site 
(NIAGADS)  
• NIAGADS provides qualified 
investigators with access to a 
national genetics data 
repository pertaining to late- 
onset AD.  
• This site ensures that 
genotypic data for the study 
of AD and related dementias 
(ADRD) are harmonized and 
shared with the research 






• Established by the National 
Institute on Aging/NIH to 
facilitate collaborative 
research by collecting data 
from 29 NIA-funded Alz-
heimer’s Disease Centers. 
NACC includes approxi-
mately 25,000 subjects, 
roughly equal parts cogni-
tively normal, MCI and 
demented.  
• Includes imaging, CSF, and 






Network (GAAIN)  
• A big-data community for 
cohort discovery and data 
exploration that promotes 
data sharing among a feder-
ated, global network of data 
partners who are studying 
AD and other dementias.  
• It is a collaborative project 
that provides researchers 
with access to clinical, 
genetic, and imaging data on 
Alzheimer’s disease from 




The Rush Alzheimer’s 
Disease Center (RADC) 
Research Resource 
Sharing Hub 
• Site for non-RADC in-
vestigators to navigate the 
complex data and bio-
specimens available for 
sharing  
• Provides assistance in 
identifying data and 
biospecimens that you can 







• Develop and execute 
innovative clinical trials 
focused on interventions 
that may prevent, delay, or 
treat the expression of AD 
and related dementias  
• Committed to sharing 
resources and tools 
including data, 
biospecimens, trial designs, 
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and synaptic signaling subtypes were developed (Neff et al., 2021). 
These subtypes are well represented in complementary mouse models, 
including the AD-BXD mouse panel (Philip et al., 2021, unpublished 
personal communication). Since these subtypes were identified as in-
dependent of age and disease severity, there is potential for supple-
mental data types to be incorporated to promote the identification of 
predictive factors that can then be tested longitudinally. More specially, 
studying in vivo functional neuroimaging outcomes in combination with 
other systems biology approaches in transgenic mice may yield impor-
tant insights regarding the mechanisms that underlie the development of 
different AD subtypes (Fig. 2). 
Precision medicine is driven by the application of high-throughput 
systems biology, powerful computational and statistical modeling 
tools, and the integration of asymptomatic, preclinical, and clinical 
datasets to identify and connect novel causal mechanisms of AD (Cast-
rillo et al., 2018; Hampel et al., 2016; Hampel et al., 2018). The resulting 
subtypes and networks identified foster precise early preclinical detec-
tion, effective prevention, and personalized disease modifying treat-
ments (Collins and Varmus, 2015; Hampel et al., 2019b; Uddin et al., 
2019). To attain this level of understanding of AD mechanism and 
manifestation, large-scale model organism experiments that survey 
translatable AD biomarkers need to be performed (Fig. 2). 
5. Future directions of systems biology and use of imaging 
modalities to evaluate AD progression 
Systems biology has the potential to change how AD is defined and 
translated from bench to bedside. Human studies have demonstrated 
that identifying structural and functional relationships using in vivo 
imaging data combined with clinical outcomes has increased our un-
derstanding of disease outcomes. Expanding and building upon these 
studies using model mouse populations will allow researchers better 
control and the ability to manipulate mechanistic networks across 
various scales of biology and environmental exposures. Applying sys-
tems biology approaches to large reproducible cohorts will be a crucial 
step toward identifying predictive AD biomarkers, establishing predic-
tive models, and creating precision medicine solutions. 
While the benefits of these approaches are clear, there are current 
challenges to applying imaging modalities and systems biology. Taking a 
systems biology approach to investigating precision medicine solutions 
to AD necessitates large sample sizes. Current human studies require 
hundreds to thousands of individuals to map genetic risk loci or corre-
late biomarkers with clinical outcomes (Ard and Edland, 2011; Brook-
meyer and Abdalla, 2019; Ederer et al., 1993; Grill et al., 2013). To 
achieve more confident results from genetic mapping, the same is also 
needed in mouse studies. Large sample sizes are essential to pursue 
multimodal analyses of varying biological systems and scales. Monetary 
and time investments can also greatly influence the feasibility to com-
plete these studies, but a well powered study in an appropriate model 
has the potential to significantly contribute to the understanding and 
mechanisms of AD. Moreover, applying imaging modalities to large 
systems biology datasets requires a significant amount of data process-
ing, which presents the opportunity to introduce user bias. To combat 
this, the field is pushing towards standardization of imaging acquisition 
and processing methods (Mueller et al., 2005; Whitesell et al., 2019). 
Even when using identical mouse models and similar imaging ap-
proaches, independent labs can achieve varying results for measures like 
rate of amyloid plaque accumulation or regional levels of atrophy 
(Kolinger et al., 2021; Mannheim et al., 2018; Morbelli and Bauckneht, 
2018; Osborne et al., 2017). This lack of consistency makes it difficult to 
combine and compare results, and for these reasons, all processing pa-
rameters should be disclosed to promote reproducibility (Eisenstein, 
2020). The creation of centralized data portals and collaborative efforts 
have promoted this type of synchronicity (Hodes and Buckholtz, 2016; 
Kitano, 2002a). These sites provide researchers a platform to collabo-
rate, contribute their own data, or to analyze data from other groups 
(Table 3). Furthermore, another area the AD imaging field can improve 
upon is in the analysis of subjective regions of interest (Simpson et al., 
2021). Manual stereology or delineation is based on the user’s experi-
ence and anatomical knowledge. Even the scope and use of machine 
learning and artificial intelligence guided methods is biased by users as 
they set training parameters. Use of more automated pipelines and 
standard brain atlases aid in reducing the subjectivism of quantifying 
and reporting region specific measures (Bjerke et al., 2018; Boline et al., 
2008; Hawrylycz et al., 2011; Hjornevik et al., 2007; Johnson et al., 
2010; Wang et al., 2020). High throughput studies including many re-
gions of interest or brain-wide approaches can give a more compre-
hensive large-scale look at the changes that occur with disease status. 
6. Conclusion 
Integrating multiple imaging modalities with the various omics of 
systems biology permits a thorough investigation of AD and its inter-
acting components across various biological systems and scales. The 
need to incorporate many imaging and omics methods to study indi-
vidual humans or mouse strains pays tribute to the complexity of this 
disease. Modelling AD in mice offers the advantage of parsing out the 
interacting components underlying AD manifestation in a controlled 
fashion. Evaluating a wide variety of strains, samples, and methods 
within translationally relevant mouse panels enables researchers to 
untangle the mechanisms perturbed in the different subtypes of AD. AD 
progression is viewed as a spectrum, but patterns of interacting levels of 
systems biology (e.g. genomic, transcriptomic, or metabolomics rela-
tionship to neural connectivity) are evident and are the foundation for 
classifying mouse models and human individuals into AD subtypes. 
Categorizing individuals’ disease subtypes paves the way towards fully 
understanding the complexity of AD, how it manifests differently among 
individuals, and eventually, precision medicine solutions. 
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Tesí, N., Thalamuthu, A., Tegos, T., Traykov, L., Tremolizzo, L., Tybjærg-Hansen, A., 
Uitterlinden, A., Ullgren, A., Ulstein, I., Valero, S., Van Broeckhoven, C., Van Der 
Lugt, A., Van Dongen, J., Van Rooij, J., Van Swieten, J., Vandenberghe, R., 
Verhey, F., Vidal, J.-S., Vogelgsang, J., Vyhnalek, M., Wagner, M., Wallon, D., 
Wang, L.-S., Wang, R., Weinhold, L., Wiltfang, J., Windle, G., Woods, B., 
Yannakoulia, M., Zhao, Y., Zulaica, M., Serrano-Rios, M., Seripa, D., Stordal, E., 
Farrer, L.A., Psaty, B.M., Ghanbari, M., Raj, T., Sachdev, P., Mather, K., Jessen, F., 
Ikram, M.A., De Mendonça, A., Hort, J., Tsolaki, M., Pericak-Vance, M.A., 
Amouyel, P., Williams, J., Frikke-Schmidt, R., Clarimon, J., Deleuze, J.-F., Rossi, G., 
Seshadri, S., Andreassen, O.A., Ingelsson, M., Hiltunen, M., Sleegers, K., 
Schellenberg, G.D., Van Duijn, C.M., Sims, R., Van Der Flier, W.M., Ruiz, A., 
Ramirez, A., Lambert, J.-C., 2020. New Insights on the Genetic Etiology of 
Alzheimer’s and Related Dementia. Cold Spring Harbor Laboratory. 
Belloy, M.E., Napolioni, V., Greicius, M.D., 2019. A quarter century of APOE and 
Alzheimer’s disease: progress to date and the path forward. Neuron 101 (5), 
820–838. https://doi.org/10.1016/j.neuron.2019.01.056. 
Bennett, D.A., Schneider, J.A., Arvanitakis, Z., Kelly, J.F., Aggarwal, N.T., Shah, R.C., 
Wilson, R.S., 2006. Neuropathology of older persons without cognitive impairment 
from two community-based studies. Neurology 66 (12), 1837. https://doi.org/ 
10.1212/01.wnl.0000219668.47116.e6. 
Bennett, D.A., Buchman, A.S., Boyle, P.A., Barnes, L.L., Wilson, R.S., Schneider, J.A., 
2018. Religious orders study and rush memory and aging project. J. Alzheimer’s 
Disease JAD 64 (Suppl. 1), S161–S189. https://doi.org/10.3233/JAD-179939. 
Biessels, G.J., Staekenborg, S., Brunner, E., Brayne, C., Scheltens, P., 2006. Risk of 
dementia in diabetes mellitus: a systematic review. Lancet Neurol. 5 (1), 64–74. 
https://doi.org/10.1016/S1474-4422(05)70284-2. 
Bjerke, I.E., Øvsthus, M., Andersson, K.A., Blixhavn, C.H., Kleven, H., Yates, S.C., 
Puchades, M.A., Bjaalie, J.G., Leergaard, T.B., 2018. Navigating the murine brain: 
toward best practices for determining and documenting neuroanatomical locations 
in experimental studies. Front. Neuroanat. 12, 82. https://doi.org/10.3389/ 
fnana.2018.00082. 
Boekel, J., Chilton, J.M., Cooke, I.R., Horvatovich, P.L., Jagtap, P.D., Kall, L., Lehtio, J., 
Lukasse, P., Moerland, P.D., Griffin, T.J., 2015. Multi-omic data analysis using 
galaxy. Nat. Biotechnol. 33 (2), 137–139. https://doi.org/10.1038/nbt.3134. 
Bohland, J.W., Wu, C., Barbas, H., Bokil, H., Bota, M., Breiter, H.C., Cline, H.T., Doyle, J. 
C., Freed, P.J., Greenspan, R.J., Haber, S.N., Hawrylycz, M., Herrera, D.G., 
Hilgetag, C.C., Huang, Z.J., Jones, A., Jones, E.G., Karten, H.J., Kleinfeld, D., 
Kotter, R., Lester, H.A., Lin, J.M., Mensh, B.D., Mikula, S., Panksepp, J., Price, J.L., 
Safdieh, J., Saper, C.B., Schiff, N.D., Schmahmann, J.D., Stillman, B.W., Svoboda, K., 
Swanson, L.W., Toga, A.W., Van Essen, D.C., Watson, J.D., Mitra, P.P., 2009. 
A proposal for a coordinated effort for the determination of brainwide 
neuroanatomical connectivity in model organisms at a mesoscopic scale. PLoS 
Comput. Biol. 5 (3), e1000334 https://doi.org/10.1371/journal.pcbi.1000334. 
Boline, J., Lee, E.F., Toga, A.W., 2008. Digital atlases as a framework for data sharing. 
Front. Neurosci. 2 (1), 100–106. https://doi.org/10.3389/neuro.01.012.2008. 
B. Gurdon and C. Kaczorowski                                                                                                                                                                                                              
Neurobiology of Disease 161 (2021) 105558
13
Bookheimer, S.Y., Strojwas, M.H., Cohen, M.S., Saunders, A.M., Pericak-Vance, M.A., 
Mazziotta, J.C., Small, G.W., 2000. Patterns of brain activation in people at risk for 
Alzheimer’s disease. N. Engl. J. Med. 343 (7), 450–456. https://doi.org/10.1056/ 
NEJM200008173430701. 
Bouter, C., Henniges, P., Franke, T.N., Irwin, C., Sahlmann, C.O., Sichler, M.E., 
Beindorff, N., Bayer, T.A., Bouter, Y., 2018. (18)F-FDG-PET detects drastic changes 
in brain metabolism in the Tg4-42 model of Alzheimer’s disease. Front. Aging 
Neurosci. 10, 425. https://doi.org/10.3389/fnagi.2018.00425. 
Boyle, P.A., Wilson, R.S., Yu, L., Barr, A.M., Honer, W.G., Schneider, J.A., Bennett, D.A., 
2013. Much of late life cognitive decline is not due to common neurodegenerative 
pathologies. Ann. Neurol. 74 (3), 478–489. https://doi.org/10.1002/ana.23964. 
Braak, H., Braak, E., 1991. Neuropathological stageing of Alzheimer-related changes. 
Acta Neuropathol. 82 (4), 239–259. https://doi.org/10.1007/BF00308809. 
Braak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H., Del Tredici, K., 2006. Staging of 
Alzheimer disease-associated neurofibrillary pathology using paraffin sections and 
immunocytochemistry. Acta Neuropathol. 112 (4), 389–404. https://doi.org/ 
10.1007/s00401-006-0127-z. 
Brademan, D.R., Miller, I.J., Kwiecien, N.W., Pagliarini, D.J., Westphall, M.S., Coon, J.J., 
Shishkova, E., 2020. Argonaut: A web platform for collaborative multi-omic data 
visualization and exploration. Patterns (N Y) 1 (7). https://doi.org/10.1016/j. 
patter.2020.100122. 
Brier, M.R., Gordon, B., Friedrichsen, K., Mccarthy, J., Stern, A., Christensen, J., 
Owen, C., Aldea, P., Su, Y., Hassenstab, J., Cairns, N.J., Holtzman, D.M., Fagan, A. 
M., Morris, J.C., Benzinger, T.L.S., Ances, B.M., 2016. Tau and Aβ imaging, CSF 
measures, and cognition in Alzheimer’s disease. Sci. Transl. Med. 8 (338) https:// 
doi.org/10.1126/scitranslmed.aaf2362, 338ra366-338ra366.  
Brookmeyer, R., Abdalla, N., 2019. Design and sample size considerations for 
Alzheimer’s disease prevention trials using multistate models. Clin. Trials 16 (2), 
111–119. https://doi.org/10.1177/1740774518816323. 
Brown, R.K.J., Bohnen, N.I., Wong, K.K., Minoshima, S., Frey, K.A., 2014. Brain PET in 
suspected dementia: patterns of altered FDG metabolism. RadioGraphics 34 (3), 
684–701. https://doi.org/10.1148/rg.343135065. 
Buchman, A.S., Wilson, R.S., Bienias, J.L., Shah, R.C., Evans, D.A., Bennett, D.A., 2005. 
Change in body mass index and risk of incident Alzheimer disease. Neurology 65 (6), 
892–897. https://doi.org/10.1212/01.wnl.0000176061.33817.90. 
Budin, F., Hoogstoel, M., Reynolds, P., Grauer, M., O’Leary-Moore, S.K., Oguz, I., 2013. 
Fully automated rodent brain MR image processing pipeline on a Midas server: from 
acquired images to region-based statistics. Front. Neuroinform. 7, 15. https://doi. 
org/10.3389/fninf.2013.00015. 
Busche, M.A., Eichhoff, G., Adelsberger, H., Abramowski, D., Wiederhold, K.-H., 
Haass, C., Staufenbiel, M., Konnerth, A., Garaschuk, O., 2008. Clusters of 
hyperactive neurons near amyloid plaques in a mouse model of Alzheimer’s disease. 
Science 321 (5896), 1686–1689. https://doi.org/10.1126/science.1162844. 
Busche, M.A., Chen, X., Henning, H.A., Reichwald, J., Staufenbiel, M., Sakmann, B., 
Konnerth, A., 2012. Critical role of soluble amyloid-β for early hippocampal 
hyperactivity in a mouse model of Alzheimer’s disease. Proc. Natl. Acad. Sci. 109 
(22), 8740–8745. https://doi.org/10.1073/pnas.1206171109. 
Byun, M.S., Kim, S.E., Park, J., Yi, D., Choe, Y.M., Sohn, B.K., Choi, H.J., Baek, H., Han, J. 
Y., Woo, J.I., Lee, D.Y., Alzheimer’s Disease Neuroimaging, I, 2015. Heterogeneity of 
regional brain atrophy patterns associated with distinct progression rates in 
Alzheimer’s disease. PLoS One 10 (11), e0142756. https://doi.org/10.1371/journal. 
pone.0142756. 
Cai, Z., Li, S., Matuskey, D., Nabulsi, N., Huang, Y., 2019. PET imaging of synaptic 
density: a new tool for investigation of neuropsychiatric diseases. Neurosci. Lett. 
691, 44–50. https://doi.org/10.1016/j.neulet.2018.07.038. 
Cao, J., Hou, J., Ping, J., Cai, D., 2018. Advances in developing novel therapeutic 
strategies for Alzheimer’s disease. Mol. Neurodegener. 13 (1), 64. https://doi.org/ 
10.1186/s13024-018-0299-8. 
Cardenas, V.A., Chao, L.L., Studholme, C., Yaffe, K., Miller, B.L., Madison, C., Buckley, S. 
T., Mungas, D., Schuff, N., Weiner, M.W., 2011. Brain atrophy associated with 
baseline and longitudinal measures of cognition. Neurobiol. Aging 32 (4), 572–580. 
https://doi.org/10.1016/j.neurobiolaging.2009.04.011. 
Castrillo, J.I., Lista, S., Hampel, H., Ritchie, C.W., 2018. Systems biology methods for 
Alzheimer’s disease research toward molecular signatures, subtypes, and stages and 
precision medicine: application in cohort studies and trials. Methods Mol. Biol. 1750, 
31–66. https://doi.org/10.1007/978-1-4939-7704-8_3. 
Chaney, A., Bauer, M., Bochicchio, D., Smigova, A., Kassiou, M., Davies, K.E., 
Williams, S.R., Boutin, H., 2018. Longitudinal investigation of neuroinflammation 
and metabolite profiles in the APPswe xPS1Deltae9 transgenic mouse model of 
Alzheimer’s disease. J. Neurochem. 144 (3), 318–335. https://doi.org/10.1111/ 
jnc.14251. 
Charil, A., Shcherbinin, S., Southekal, S., Devous, M.D., Mintun, M., Murray, M.E., 
Miller, B.B., Schwarz, A.J., 2019. Tau subtypes of Alzheimer’s disease determined in 
vivo using flortaucipir PET imaging. J. Alzheimers Dis. 71 (3), 1037–1048. https:// 
doi.org/10.3233/JAD-190264. 
Chen, C., Liang, Z., Zhou, B., Li, X., Lui, C., Ip, N.Y., Qu, J.Y., 2018a. In vivo near-infrared 
two-photon imaging of amyloid plaques in deep brain of Alzheimer’s disease mouse 
model. ACS Chem. Neurosci. 9 (12), 3128–3136. https://doi.org/10.1021/ 
acschemneuro.8b00306. 
Chen, G.-F., Xu, T.-H., Yan, Y., Zhou, Y.-R., Jiang, Y., Melcher, K., Xu, H.E., 2017. 
Amyloid beta: structure, biology and structure-based therapeutic development. Acta 
Pharmacol. Sin. 38 (9), 1205–1235. https://doi.org/10.1038/aps.2017.28. 
Chen, M.K., Mecca, A.P., Naganawa, M., Finnema, S.J., Toyonaga, T., Lin, S.F., 
Najafzadeh, S., Ropchan, J., Lu, Y., McDonald, J.W., Michalak, H.R., Nabulsi, N.B., 
Arnsten, A.F.T., Huang, Y., Carson, R.E., van Dyck, C.H., 2018b. Assessing Synaptic 
Density in Alzheimer Disease With Synaptic Vesicle Glycoprotein 2A Positron 
Emission Tomographic Imaging. JAMA Neurol. 75 (10), 1215–1224. https://doi. 
org/10.1001/jamaneurol.2018.1836. 
Chen, W.-T., Lu, A., Craessaerts, K., Pavie, B., Sala Frigerio, C., Corthout, N., Qian, X., 
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